Login
$CCAP
$8.90 +$0.20 (2.3%) Close

Consolidated Statements of Assets and Liabilities

In millions of USD, except per-share amounts
Q2 FY2026
As of Jun 30, 2026
Q1 FY2026
As of Mar 31, 2026
Q4 FY2025
As of Dec 31, 2025
Q3 FY2025
As of Sep 30, 2025
Q2 FY2025
As of Jun 30, 2025
Q1 FY2025
As of Mar 31, 2025
Q4 FY2024
As of Dec 31, 2024
Q3 FY2024
As of Sep 30, 2024
Q2 FY2024
As of Jun 30, 2024
Q1 FY2024
As of Mar 31, 2024
Q4 FY2023
As of Dec 31, 2023
Q3 FY2023
As of Sep 30, 2023
Q2 FY2023
As of Jun 30, 2023
Q1 FY2023
As of Mar 31, 2023
Q4 FY2022
As of Dec 31, 2022
Q3 FY2022
As of Sep 30, 2022
Assets
Investments, at fair value
Non-controlled non-affiliated
Non-controlled affiliated
Controlled
Total investments, at fair value
Cash and cash equivalents
Restricted cash and cash equivalents
Interest and dividend receivable
Receivable from unsettled transactions
Unrealized appreciation on foreign currency forward contracts
Deferred tax assets
Other assets
Total assets
Liabilities
Debt (net of deferred financing costs of $9,527 and $5,841 respectively)
Distributions payable
Interest and other debt financing costs payable
Management fees payable
Incentive fees payable
Deferred tax liabilities
Directors’ fees payable
Unrealized depreciation on foreign currency forward contracts
Unrealized depreciation on interest rate swaps
Accrued expenses and other liabilities
Total liabilities
Net assets
Common stock, par value $0.001 per share (200,000,000 shares authorized, 36,845,952 and 36,969,285 shares issued and outstanding, respectively)
Paid-in capital in excess of par value
Accumulated earnings (loss)
Total net assets
Total liabilities and net assets
Net asset value per share

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support